Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Agenix Discloses Plans for Clinical Trial of Hepatitis B Drug

publication date: Jun 8, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Agenix released a long-lead schedule for China approval of its new treatment for hepatitis B, AGX-1009. If everything goes according to plan, the company will apply in Q2 of 2012 to begin clinical trials of the drug. The trials themselves could start as early as late 2012. Agenix is developing the drug in partnership with the Institute of Medicinal Biotechnology (IMB), located in Beijing, a division of the Chinese Academy of Medical Sciences. More details....

Stock Symbol: (ASX: AGX)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
Hope to see you there!
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors